Lilly weight-loss pill orforglipron could get FDA approval in 2026, CEO Dave Ricks says


Eli Lilly & Co., the Fortune 500 pharma firm that manufactures weight-loss injection Zepbound (tirzepatide), has a comparable oral medication in the works that could be approved by the FDA as early as 2026, CEO Dave Ricks told Bloomberg TV on Jan. 13, 2025.

Gam1983/Getty Images

Lindsey Leake

Related Posts

Trump floated the idea of a 15% government stake in a massive railroad merger

President Donald Trump recently expressed interest in the federal government acquiring a 15% stake in a massive railroad merger—remarks that took on new resonance this week when a federal regulator…

Meet the founder who turned his hotel night shifts as a 14-year-old into a $2.5 billion company

Richard Valtr built one of the most valuable hospitality technology companies in the world simply because he was a teen who wanted to stop working the night shift. “I always…

You Missed

No deal announced after Trump meeting to make 'final determination' on Iran

  • By admin
  • May 30, 2026
  • 3 views
No deal announced after Trump meeting to make 'final determination' on Iran

Rescuers Free Miner Trapped Inside a Cave in Laos

Rescuers Free Miner Trapped Inside a Cave in Laos

Trump floated the idea of a 15% government stake in a massive railroad merger

Trump floated the idea of a 15% government stake in a massive railroad merger

Star Sightings: Olivia Rodrigo Wears a ‘Saturday Night Live’ Jacket, Emily Ratajkowski Shops in New York City

Star Sightings: Olivia Rodrigo Wears a ‘Saturday Night Live’ Jacket, Emily Ratajkowski Shops in New York City

Eight students arrested in Kenya after suspected deadly school arson attack

  • By admin
  • May 29, 2026
  • 4 views
Eight students arrested in Kenya after suspected deadly school arson attack

Off the Bone Came Before All of Them

Off the Bone Came Before All of Them